Clinical trial
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
NCT00076037 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00076037 |
|---|---|
| Title | Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP |
| Official title | A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological, Drug |
| Interventions | HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF |
| Enrollment | 96 |
| Start date | Apr 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Jan 14, 2004 |
| Last update posted | Oct 14, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: